Abstract
Estrogen receptor immunohistochemistry should not be used in the clinic as an indicator of response to antihormonal therapy; progesterone receptor immunohistochemistry may be prognostic, but further study is needed. Multigene assays to assess for estrogen receptor pathway activation hold potential as a viable diagnostic tool to help determine those patients least likely to respond to single‐agent endocrine therapy and potentially identify patients most appropriate for combination strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
